The research and development capacity is the key value of a pharmaceutical company. Auriga International makes it its priority by investing 15% of its turnover annually in R&D.

Since its creation, Auriga International has implemented a “Research and Development” strategy which consists of:

• Supporting its research on a team of researchers of a very high level, who work in close collaboration with academic institutions and biotechnology companies
• Surrounding itself by a medical committee composed of dermatologists and plastic surgeons.

The establishment of this research strategy generates:

• constant innovation, headed by many patents
• a broadening of the Auriga International product range by 2 or 3 new products each year

Alfred Marchal, CEO of Auriga International “As a scientist, I am convinced that only solid research in accord with market needs will lead to success, as has been demonstrated since the creation of Auriga International”